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In this study, we show differential associations between cannabis use, and apathy and 
anhedonia, for adults and adolescents. Adolescent cannabis users had higher levels of 
anhedonia compared to age-matched controls, whereas adult users had lower levels of apathy 
and anhedonia compared to age-matched controls. Cannabis dependence was associated with 
higher levels of apathy and anhedonia within both adult and adolescent users. These results 
indicate that individual differences within cannabis users may be more important than user 
status per se, in predicting apathy and anhedonia. We also found that levels of apathy and 
anhedonia had increased since the onset of the COVID-19 lockdown, and that this increase 
was larger in dependent compared to non-dependent cannabis users. Our results add to the 
growing body of evidence on the adverse mental health impact of the COVID-19 lockdown, 



















Background: COVID-19 lockdown measures have caused severe disruptions to work and 
education, and prevented people from engaging in many rewarding activities. Cannabis users 
may be especially vulnerable, having been previously shown to have higher levels of apathy 
and anhedonia than non-users.  
Methods: In this survey study, we measured apathy and anhedonia before and after 
lockdown measures were implemented, in n=256 adult and n=200 adolescent cannabis users, 
and n=170 adult and n=172 adolescent controls. Scores on the Apathy Evaluation Scale 
(AES) and Snaith-Hamilton Pleasure Scale (SHAPS) were investigated with mixed measures 
Analyses of Covariance, with factors User-Group, Age-Group, and Time, controlling for 
depression, anxiety, and other drug use.  
Results: Adolescent cannabis users had significantly higher SHAPS scores before lockdown, 
indicative of greater anhedonia, compared to adolescent controls (p=.03, ηp
2
=.013). 
Contrastingly, adult users had significantly lower scores on both the SHAPS (p<.001, 
ηp
2
=.030) and AES (p<.001, ηp
2
=.048) after lockdown, compared to adult controls. Scores on 
both scales increased during lockdown across groups, and this increase was significantly 
smaller for cannabis users (AES p=.001, ηp
2
=.014; SHAPS p=.01, ηp
2
=.008). Exploratory 
analyses revealed that dependent cannabis users had significantly higher scores overall (AES 
p<.001, ηp
2
=.037; SHAPS p<.001, ηp
2
=.029), and a larger increase in scores (AES p=.04, ηp
2
 
.010; SHAPS p=.04, ηp
2
=.010), compared to non-dependent users.  
Conclusions: Our results suggest that adolescents and adults have differential associations 
between cannabis use, and apathy and anhedonia. Within users, dependence may be 
associated with higher levels of apathy and anhedonia regardless of age, and a greater 












The COVID-19 pandemic is a global public health crisis. Lockdown measures 
intended to mitigate the spread of the virus have imposed a significant constraint on our 
ability to engage in activities we normally find rewarding, and many have reported feeling a 
loss of motivation and purpose during the pandemic (Minds, 2020). Meanwhile, the use of 
cannabis appears to have increased (Winstock et al., 2020). Though the association between 
cannabis and reward processing is unclear, some previous research has linked cannabis use 
with reduced motivation (Pacheco-Colón et al., 2018a), placing users at potentially increased 
risk of anhedonic and amotivational responses to COVID-19 lockdown measures.  
Cannabis use has been associated with syndromes of reward and motivation, 
including apathy (Meier and White, 2018; Petrucci et al., 2020) and anhedonia (Dorard et al., 
2008; Leventhal et al., 2017; Lopez-Vergara et al., 2019). Apathy refers to a loss of or 
reduction in motivation, and anhedonia to a loss of interest in or pleasure from previously 
rewarding activities (Robert et al., 2009; Treadway and Zald, 2011). One recent large-scale 
study by Petrucci et al. (2020) found that problematic cannabis use correlated with apathy, 
and a longitudinal study of over 3000 participants by Leventhal et al. (2017) found that 
anhedonia predicted future cannabis use during adolescence. Adolescents may be predisposed 
towards harmful effects of cannabis, including apathy and anhedonia, due to the important 
neuromaturation that takes place during this time (Bossong and Niesink, 2010; Lubman et al., 
2015). However, some studies do not find higher levels of apathy or anhedonia in cannabis 
users (Dumas et al., 2002; Barnwell et al., 2006; Pacheco-Colón et al., 2018b), thus more 
research is needed to understand this relationship. 
Research on the impact of COVID-19 is in its early stages. Some systematic reviews 











which has increased since the onset of the pandemic (Li and Wang, 2020; Luo et al., 2020; 
Pierce et al., 2020; Xiong et al., 2020). Social distancing has meant increased isolation and 
loneliness, which are important risk factors for mental health problems (Vatansever et al., 
2021), and negatively impact social cognition (Bland et al., 2020). These measures may be 
especially hard on adolescents, given the particular importance of peer interaction during this 
time (Blakemore, 2008; Kilford et al., 2016). Indeed, several studies suggest that adolescents 
have faced severe psychosocial consequences due to lockdown (Duan et al., 2020; Loades et 
al., 2020; Minds, 2020), and that vulnerable adolescents are at particular risk (Fegert et al., 
2020). The COVID-19 lockdown could also have potentiated the relationship between 
cannabis use and apathy and anhedonia. Cannabis users experiencing problems related to 
abuse and dependence may have had particular difficulty coping with the additional stress 
brought on by the pandemic. Finally, these vulnerability factors could interact and exacerbate 
problems (Fegert et al., 2020), thus placing adolescent cannabis users at enhanced risk. 
In the current study, we compared levels of apathy and anhedonia in adult and 
adolescent cannabis users and controls, both before and after COVID-19 lockdown measures 
were implemented in most European countries in mid-March 2020. The study had two aims. 
The first was to investigate whether cannabis users, and adolescent users in particular, had 
higher levels of apathy and anhedonia, compared to controls. With respect to our first aim, we 
proposed the following hypotheses: 
1. Cannabis users will have greater levels of apathy and anhedonia compared to 
controls before and after lockdown.  
2. There will be a larger difference between adolescent users and controls, than 











The second aim of this study was to investigate whether there had been an increase in 
levels of apathy and anhedonia as a result of the COVID-19 lockdown, and whether this 
increase had been more pronounced for cannabis users and adolescents. We proposed the 
following hypotheses: 
3. Levels of apathy and anhedonia will have increased since lockdown measures 
were implemented in March 2020. 
4. This increase will be larger for cannabis users compared to controls. 
5. This increase will be larger for adolescent users compared to adult users. 
2. Methods 
2.1 Participants 
This is an online survey study. The survey was advertised through relevant mailing 
lists, and on Facebook and Instagram, and responses were collected between 4
th
 of June and 
4
th
 of August 2020. Inclusion criteria were being between 16 and 30 years of age, fluent or 
almost fluent in English, and currently and normally residing in the UK, EU, EEA, or 
Switzerland. Participants were classified as cannabis users if they had used cannabis 
minimum four days per month in the three-month period before lockdown was initiated in the 
UK (i.e. the 23
rd
 of March 2020), and controls if they had used less than this. Adolescents 
were 16-17 years of age, and adults were 18-30 years of age. Eighteen participants were 
excluded from analyses (15 did not report levels of depression and/or anxiety and 3 were 
identified as giving unreliable responses) resulting in a final sample of 798 participants. 
There were 200 adolescent users, 172 adolescent controls, 256 adult users, and 170 adult 
controls. Ethical approval was obtained from the University of Cambridge Psychology 











participating in the study. Participants were provided with the option to enter a prize draw of 
three £100 gift certificates.  
2.2 Measures 
Participants completed an online questionnaire including detailed questions about 
cannabis and other drug use before and during the COVID-19 lockdown, and changes in life 
circumstances due to COVID-19. Participants were also asked if they were currently 
experiencing or had ever experienced a number of different psychiatric disorders, and asked 
to rate the impact of the pandemic on their mental health on a scale from -5 (a lot worse) to 5 
(a lot better). Cannabis dependence was assessed with the Severity of Dependence Scale 
(SDS; Gossop et al., 1995; Martin et al., 2006).  
Anhedonia was measured with the Snaith-Hamilton Pleasure Scale (SHAPS; Snaith et 
al., 1995). The SHAPS consists of 14 items covering a wide range of pleasurable experiences, 
and is a reliable and valid measure of anhedonia both in adult (Franken et al., 2007) and 
adolescent (Leventhal et al., 2015) samples. Apathy was measured with the Apathy 
Evaluation Scale (AES; Marin et al., 1991). The AES is an 18-item self-report questionnaire 
with cognitive, behavioural, and emotional dimensions, and has been demonstrated as valid 
and reliable (Raimo et al., 2014; Lueken et al., 2017). Responses on both scales were coded 
so that higher scores indicated higher levels of apathy or anhedonia, respectively. Participants 
completed the AES and SHAPS twice – once answering regarding the three-month period 
before lockdown, and once answering regarding the past two weeks at the time of responding. 













Scores on the SHAPS and AES before and after lockdown served as dependent 
variables in separate mixed measures Analyses of Covariance (ANCOVAs). Time (before 
and after lockdown) was the within-subjects factor, and User-Group and Age-Group were 
between-subject factors. The User-Group*Age-Group, User-Group*Time, Age-Group*Time, 
and User-Group*Age-Group*Time interactions were also included. Significant effects were 
followed up with post hoc ANCOVAs. Covariates in all models were days per month of 
alcohol use, days per month of cigarette use, regular illicit drug use (yes/no), self-reported 
depression (yes/no), and self-reported anxiety (yes/no), as well as all individual two-way 
covariate interactions with Time. These covariates were included due to their potential 
interaction with cannabis use (e.g. Patton et al., 2002; Fergusson et al., 2006; Millar et al., 
2021), and to separate apathy and anhedonia from general anxiety and depression. Multiple 
comparisons correction was performed using the Benjamin-Hochberg false discovery rate 
(FDR) procedure for AES and SHAPS independently for the effects of interest, with a priori 
q < .05. Partial eta squared (ηp
2
) values were used as measures of effect size. Finally, 
bivariate Pearson correlations were computed between variables of interest. Analyses were 
performed using IBM SPSS 27 and R 3.6.2 (R Core Team, 2019). 
3. Results 
3.1 Sample Characteristics  
Sample characteristics are presented in Table 1. The groups were well balanced with 
respect to age and gender, and 96.7% were residents in the United Kingdom. Adult users 
more frequently reported taking medication for a psychiatric or neurological condition (23%) 












[TABLE 1 APPROXIMATELY HERE] 
 
Cannabis use variables are presented in Table 2. Adult users reported using cannabis 
more days per month, on average, compared to adolescent users, and had a higher average 
SDS score. Using the recommended cut-off score of 3 for adults and 4 for adolescents (Swift 
et al., 1998; Martin et al., 2006), n = 130 adults (50.8%) and n = 69 adolescents (34.5%) met 
the criteria for cannabis dependence. Supplemental figure S1 shows the distribution of days 
per month of cannabis use for users and controls before and after lockdown. Although the 
majority retained the same user status, n = 25 controls (7.3%) reported using cannabis more 
than three days per month after lockdown, and n = 65 cannabis users (14.3%) reported using 
cannabis less than four days per month after lockdown.  
Cronbach’s alpha values were 0.86 and 0.90 for AES scores before and after 
lockdown, respectively, and 0.88 and 0.91 for SHAPS scores before and after lockdown, 
respectively. Bivariate correlations for variables of interest are presented in Supplemental 
Table S2. 
 
[TABLE 2 APPROXIMATELY HERE] 
3.2 Main Analyses 
Figure 1 shows mean scores and standard errors on the AES and SHAPS scales for 
the four groups, before and after lockdown. Supplemental figures S3 and S4 show score 
distributions for the four groups, before and after lockdown. Full results for AES and SHAPS 
ANCOVAs, including covariates, are displayed in supplemental tables S5 and S6. All p-












The repeated measures ANCOVA for AES yielded a significant within-subjects main 
effect of Time (F1,789 = 83.44, p < .001, ηp
2
 = .096), as well as significant interaction effects 
for Time*User-Group (F1,789 = 11.22, p = .001, ηp
2
 = .014) and Time*Age-Group (F1,789 = 
6.19, p = .01, ηp
2
 = .008), suggesting that scores had increased since lockdown across groups, 
and that this increase was larger for adolescents and controls than for adults and users. The 
Time*User*Age interaction was not significant (F1,789 = .70, p = .40). There were also 
significant between-subjects main effects of User-Group (F1,789 = 11.89, p = .001, ηp
2
 = .015) 
and Age-Group (F1,789 = 11.27, p = .001, ηp
2
 = 014), and a significant User-Group*Age-
Group interaction (F1,789 = 4.19, p = .04, ηp
2
 = .005). Four post hoc univariate ANCOVAs 
with factor User-Group were conducted separately for adults and adolescents for scores 
before and after lockdown. There were no significant differences between adolescent users 
and controls (F1,365 = .02, p = .90 before lockdown, F1,365 = 1.89, p = .17 after lockdown), but 
adult users scored lower than adult controls both before (F1,419 = 4.00, p = .046, ηp
2
 =  .009) 
and after (F1,419 = 21.10, p < .001, ηp
2
 = .048) lockdown.  
 
SHAPS 
The repeated measures ANCOVA for SHAPS yielded a marginally significant within-
subjects main effect of Time (F1,789 = 3.54, p = .06, ηp
2
 = .004), and a significant Time*User-
Group interaction effect (F1,789 = 6.49, p = .01, ηp
2
 = .008) in the direction of greater increase 
in scores from before to after lockdown for controls compared to users. Figure 1 shows that 
scores increased by only a marginal amount for users. The Time*Age and Time*User*Age 
interaction effects were not significant (F1,789 = .07, p = .80 and F1,789 = .28, p = .60, 











7.86, p = .005, ηp
2
 = .010) and User-Group*Age-Group (F1,789 = 14.53, p < .001, ηp
2
 = .018). 
Post hoc ANCOVAs conducted separately for adults and adolescents for scores before and 
after lockdown suggested that adult users scored lower than adult controls both before (F1,419 
= 3.84, p = .051, ηp
2
 = .009) and after (F1,419 = 13.05, p < .001, ηp
2
 =  .030) lockdown, 
whereas adolescent users scored higher than adolescent controls before lockdown (F1,365 = 
4.71, p = .03, ηp
2
 = .013) but not after lockdown (F1,365 = .11, p = .74). 
 
[FIGURE 1 APPROXIMATELY HERE] 
Figure 1. Means and standard errors for the Apathy Evaluation Scale and Snaith-Hamilton Pleasure 
Scale by group before and after lockdown. Higher scores indicate higher levels of apathy and 
anhedonia, respectively.      
 
Both main AES and SHAPS models were rerun excluding those subjects who 
changed user status from before to after lockdown, according to the cut-off at four days per 
month for users. Excluding these subjects did not have a marked impact on results (tables S5 
and S6). There were no significant correlations between days/month of cannabis use and AES 
and SHAPS scores either before or after lockdown (Table S2), indicating that frequency of 
use was not related to apathy or anhedonia. 
3.3 Follow-up Analyses for SDS Scores 
Bivariate correlations revealed significant positive associations between SDS and 
AES scores before (r = .21, p < .001) and after (r = .26, p < .001) lockdown, and between 
SDS and SHAPS scores before (r = .13, p = .006) and after (r = .22, p < .001) lockdown in 











relationship more closely, we performed exploratory repeated-measures ANCOVAs identical 
to the main analyses, but with Dependence (yes/no) as determined by the SDS instead of 
User-Group as the main predictor. FDR correction with a priori q < .10 was used (Genovese 
et al., 2002). Four cannabis users were missing SDS scores, and were therefore not included 
in the exploratory analyses. Full results of these models are presented in Supplemental Table 
S7. Both models showed a significant between-subjects effect of Dependence (F1,443 = 17.05, 
p <.001, ηp
2
 = .037 for AES, F1,443 = 13.07, p <.001, ηp
2
 = .029 for SHAPS), indicating that 
dependent cannabis users had higher levels of apathy and anhedonia overall. Additionally, 
there was a significant Time*Dependence interaction effect in both models (F1,443 = 4.47, p = 
.04, ηp
2
 = .010 for AES, F1,443 = 4.25, p = .04, ηp
2
 = .010 for SHAPS), suggesting a greater 
increase in levels of apathy and anhedonia from before to after lockdown in dependent 
cannabis users. There were no significant interaction effects of Dependence*Age (p = .36 for 
AES, p = .15 for SHAPS) or Time*Dependence*Age (p = .59 for AES, p = .96 for SHAPS). 
The main effects of Age, and the Time*Age interaction effects, did not change markedly 
relative to the main models. All p-values below .05 survived the FDR correction. Figure 2 
shows mean scores on the AES and SHAPS before and after lockdown by dependence and 
age.  
[FIGURE 2 APPROXIMATELY HERE] 
Figure 2. Means and standard errors for the Apathy Evaluation Scale and Snaith-Hamilton Pleasure 
Scale by level of dependence within cannabis users before and after lockdown. Higher scores indicate 














4.1 Apathy and Anhedonia in Adult and Adolescent Cannabis Users and Controls 
Adolescent cannabis users had the highest levels of apathy and anhedonia overall, but 
the difference between adolescent cannabis users and controls was only statistically 
significant for anhedonia before lockdown. Adolescent users scored on average 2.16 points 
higher than adolescent controls on the SHAPS, representing a small effect size (ηp
2
 = .013). 
Conversely, adult cannabis users had significantly lower levels of both apathy and anhedonia 
compared to adult controls at both timepoints. The mean difference in scores between adult 
users and controls was marginal before lockdown for both the AES and SHAPS (<1 point, 
see Figure 1), corresponding to small effect sizes (ηp
2
 = .009). The differences between adult 
users and controls after lockdown were substantially larger (ηp
2
 = .048 for AES, ηp
2
 = .030 
for SHAPS), and are likely attributable to the larger increase in apathy and anhedonia levels 
among adult controls compared to adult users. 
As adults used cannabis more frequently and were more dependent on average than 
adolescents, the difference between adult and adolescent user groups is unlikely to be due to 
differences in cannabis use. Rather, adolescent cannabis users might be more vulnerable to 
apathy compared to adult cannabis users, and to anhedonia compared to adult users and 
adolescent controls. There are several potential explanations for this enhanced vulnerability 
in adolescents. Adolescence is an important period of prolonged neuromaturation during 
which external factors, such as cannabis use, may be especially powerful in influencing brain 
and cognitive development (Bossong and Niesink, 2010; Lubman et al., 2015). Prolonged 
cannabis exposure during adolescence could contribute to blunted reward processing in the 
brain, increasing the susceptibility to anhedonia (Volkow et al., 2017). However, one large 
longitudinal study by Leventhal et al. (2017) found that cannabis use did not predict future 











suggest that anhedonia might be a contributing factor to cannabis use in adolescence, or 
might co-occur with other factors which predict cannabis use.  
Importantly, while adolescent cannabis users had higher levels of both apathy and 
anhedonia than the other groups, most differences between adolescent users and controls 
were not statistically significant after controlling for covariates. The effect of the depression 
covariate was large in both models (see tables S5 and S6), with a smaller, though statistically 
significant effect of anxiety. Current depression and anxiety were endorsed more frequently 
by adolescent users than by any other group. Thus, depression and anxiety might be more 
important than cannabis use in predicting blunted reward and motivation during adolescence.  
 
4.2 Increases in Apathy and Anhedonia During the COVID-19 Lockdown 
Our results showed that levels of both apathy and anhedonia increased during 
lockdown, as predicted by our first hypothesis. The increase in apathy was particularly large, 
corresponding to a medium-to-large effect size (ηp
2
 = .096), and was significantly higher for 
adolescents compared to adults. Contrary to our second hypothesis, levels of apathy and 
anhedonia rose less for cannabis users than controls during the COVID-19 lockdown. 
The adolescents in our sample reported COVID-19-related interruptions to their work 
or studies more frequently than adults, and a more negative mental health impact of COVID-
19, on average (see Table 1). Thus, adolescents may have faced more severe disruptions to 
their life and mental health as a result of the pandemic, which could explain the greater 
increase in apathy in this age group. The unexpected smaller increase in scores among 
cannabis users compared to controls could be due to the fact that while lockdown has kept 
people from engaging in activities they normally find enjoyable, it has not prevented users 











pandemic, partly in order to counteract the boredom that comes with being under strict social 
distancing regulations (Winstock et al., 2020). This was also the case in the present sample. 
Thus, for users, cannabis may have been an easily accessible coping strategy to deal with the 
monotony of lockdown. Additionally, cannabis users were less likely to report compliance 
with stay-at-home recommendations (see Table 1), which could have contributed to this 
result.  
 
4.3 Apathy and Anhedonia in Dependent and Non-dependent Cannabis Users 
Among cannabis users, those who were categorised as dependent on the SDS had 
significantly higher levels of apathy (ηp
2
 = .037) and anhedonia (ηp
2
 = .029) than those who 
were not dependent, corresponding to small-to-medium effect sizes. Levels of apathy and 
anhedonia also increased more for dependent compared to non-dependent users during the 
COVID-19 lockdown. 
There were no significant correlations between days per month of cannabis use and 
AES or SHAPS scores within the user group (see Table S2). Higher levels in dependent users 
cannot, therefore, be attributed to higher use frequency. Instead, our results suggest that 
cannabis dependence is a more important predictor of apathy and anhedonia than cannabis 
use per se. Cannabis users who go on to develop dependence may have worse mental health 
compared to those who do not develop dependence (Marel et al., 2019), as well as potentially 
increased risk of depressive symptoms with chronic stress exposure (Sidhpura and Parsons, 
2011; Volkow et al., 2017). In the current sample, dependent users did indeed report mental 
health problems more frequently than did non-dependent users, though current anxiety and 
depression were controlled in all analyses. Cannabis dependence might thus be a marker of 











contribute to lower resilience to prolonged stressors like the COVID-19 pandemic. 
Additionally, dysregulated reward processing features centrally in theories of substance use 
disorder (e.g. Blum et al., 2000; Berridge and Robinson, 2016; Koob and Volkow, 2016). 
From this perspective, apathy and anhedonia might be considered characteristic of cannabis 
dependence, providing an alternative explanation of the present findings.  
It is worth making a final remark on the relative effects of age and dependence on 
apathy and anhedonia. While we did not conduct a formal analysis comparing controls with 
dependent and non-dependent users, the results of the exploratory analyses suggest that the 
significant between-group differences in the main analyses were chiefly driven by adolescent 
dependent users and adult non-dependent users. Both adolescent age and cannabis 
dependence increased the vulnerability of cannabis users to apathy and anhedonia, and their 
effects appeared to be additive.  
 
4.4 Limitations 
The current study has several strengths including the large, well-balanced sample and 
adjustment with relevant confounders. An important limitation is the retrospective, rather 
than prospective assessment of pre-pandemic cannabis use and apathy and anhedonia. 
However, given the abrupt changes in circumstances of the pandemic lockdown, it was hard 
to avoid this limitation. Another limitation concerns group characteristics. Firstly, the adult 
age group included younger adults, which means the current findings may not generalise to 
older adults (>30 years). Secondly, although we controlled for several important covariates, 













To our knowledge, this is the first study to look at the impact of the COVID-19 
pandemic lockdown on a mental health outcome in cannabis users compared to controls. 
Several conclusions can be drawn. Firstly, our results suggest that adolescent cannabis users 
have higher levels of anhedonia compared to adolescent controls, and higher levels of apathy 
and anhedonia compared to adult users. There was no evidence of higher apathy or anhedonia 
in adult cannabis users, compared to controls. Secondly, within users, cannabis dependence is 
associated with significantly higher levels of both apathy and anhedonia. These results 
suggest that individual differences within cannabis users may be more important than user 
status per se, in predicting apathy and anhedonia with cannabis use, and that adolescent 
dependent users might be particularly vulnerable. Future studies should investigate which 
factors make some cannabis users especially vulnerable to apathy and anhedonia, in addition 
to age and dependence.  
Our results also suggest that the COVID-19 lockdown has had a significant negative 
impact on hedonic processing and motivation, and that adolescents and people with substance 
dependence may be more vulnerable. Future research should continue to track the mental 
health of both cannabis users and controls after lockdown measures have ended, so that 
existing and novel treatment and prevention strategies can be rapidly employed to mitigate 















(n = 200) 
Adolescent 
controls 
(n = 172) 
Adult users 
 
(n = 256) 
Adult 
controls 




Gender f/m/other, n 104/93/3 87/80/5 126/121/9 83/78/9  

























































































Depression, n (%) 
Yes, currently 




















Anxiety, n (%) 
Yes, currently 




















COVID-19 impact on 
employment/study 
status, n (%)  
1 No change 
2 Working from home 
3 Part/complete 
furlough, or disrupted/ 
postponed studies 











































COVID-19 impact on 







































No 154 (77.00) 134 (77.91) 197 (76.95) 144 (84.71) 
Lost a loved one to 
























Table 1. Sample characteristics 
Abbreviations. f – female, m – male 
Note. Other drug use classified as yes if the participant had used any of the following drugs at least 
once per month over the past three months: 3,4-Methylenedioxymethamphetamine (MDMA), cocaine, 
nitrous oxide (laughing gas), ketamine, psilocybin/magic mushrooms, lysergic acid diethylamide 
(LSD), methamphetamine, heroin. User-Group comparisons were performed with independent 
samples t-tests for scaled variables, and with Pearson chi-square tests for binarized count variables 
(current depression yes/no, current anxiety yes/no, COVID-19 employment/study categories 1 and 2 















(n = 200) 
Adolescent 
controls 
(n = 172) 
Adult users 
 
(n = 256) 
Adult 
controls 






mean (SD), range 

























Ever use, n (%) NA 65 (37.79) NA 105 (61.76) <.001 
Ever regular use, 
n (%) 
NA 7 (4.07) NA 41 (24.12) <.001 
Age of first use, 
mean (SD) 
14.18 (1.18) 14.86 (1.00) 
n = 65 
16.20 (2.04) 16.75 (2.42) 
n = 105 
<.001 (users) 
<.001 (controls) 
Age of regular 
use, mean (SD) 
15.84 (0.91) 
n = 199 
15.71 (0.95) 
n = 7 
19.11 (2.42) 
n = 253 
17.80 (2.79) 
n = 41 
<.001 (users) 
.001 (controls) 
SDS, mean (SD) 3.02 (2.96) 
n = 199 
2.17 (1.33) 
n = 6 
3.53 (3.32) 
n = 253 
2.18 (1.94)  
n = 17 
.09 (users) 
.99 (controls) 
Table 2. Cannabis use variables 
Abbreviations. NA – not applicable, SDS – Severity of Dependence Scale 
Note. The SDS is reported for controls who used cannabis ≥4 days per month after lockdown. Age-
Group comparisons were made within users and controls, with independent samples t-tests for scaled 
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